Where is Anew located?

Anew is headquartered in China.

Is Anew a funded company?

Anew is a funded company, having raised a total of $***** in its 1st and only funding round, a Series D round on Sep 17, 2026.

When was the latest funding round of Anew?

Anew's latest funding was a $***** Series D round on Sep 17, 2026, with participation from 8 investors.

Where does Anew rank among its competitors?

Anew ranks 86th amongst 282 active competitors, of which 86 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Anew, which secured $290M in Sep, 2026.

Who are the top competitors of Anew?

Anew's top competitors include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Among them, Anew secured the most recent funding round in September, 2026.

Anew - 2026 Company Profile, Funding & Competitors

Anew is a series D company based in China. It operates as a Developer of artificial intelligence platforms for drug discovery and design. Anew has raised $290M in funding from investors like IDG Capital, HSG and Hillhouse. The company has 282 active competitors, including 86 funded and 15 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics.

Company Details

Developer of artificial intelligence platforms for drug discovery and design. These computational systems integrate protein structure prediction, molecular dynamics, and generative modeling to identify therapeutic targets and optimize small-molecule and antibody candidates. The technology utilizes scientific reasoning models and experimental feedback loops to facilitate the generation of synthesis pathways and the evaluation of biomolecular interactions. This approach supports the progression of pharmaceutical candidates from initial identification through to clinical development stages.

Key Metrics

Location

China

Stage

Series D

Total Funding

$290M in 1 round

Latest Funding Round

Series D, Sep 17, 2026, $*****

Investors

IDG Capital & 7 more

Ranked

86^th among 282 active competitors

Similar Companies

Schrodinger & 284 more

View Anew's full profile

Anew has raised a total funding of $290M over 1 round. Its latest funding round was a Series D round on Sep 17, 2026 for $*****. 8 investors participated in its latest round. Anew has 8 institutional investors.

Here is the list of recent funding rounds of Anew:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2026	5642991	Series D	2128911	4194109	6405579	3104858

Access funding benchmarks and valuations. Sign up today!

View details of Anew's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Anew include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Here is the list of Top 10 competitors of Anew, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 48 others	72/100
3rd	Relay Therapeutics 2016, Cambridge (United States), Public	Developer of drug discovery platform and study protein motion	$520M	BVF Partners, SoftBank Vision Fund & 17 others	70/100
4th	Atomwise 2012, San Francisco (United States), Series B	Developer of artificial intelligence platform for small molecule drug discovery	$219M	DCVC, B Capital & 27 others	67/100
5th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	67/100
6th	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Orbimed & 25 others	67/100
7th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
8th	In Silico 2014, Boston (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Value Partners & 36 others	63/100
9th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
10th	Genesis Therapeutics 2019, San Francisco (United States), Series B	Developer of an AI platform for discovering and designing novel drugs	$304M	Andreessen Horowitz, Rock Springs Capital ... & 16 others	62/100
86th	Anew China, Series D	Developer of artificial intelligence platforms for drug discovery and design	$290M	Hillhouse, Primavera & 6 others	34/100